Nanjing Vazyme Biotech Co., Ltd. (688105.SS)
CNY 23.21
(-1.9%)
CNY 23.21
(-1.9%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -70.95 Million CNY | -111.94% |
| 2022 | 594.24 Million CNY | -12.39% |
| 2021 | 678.28 Million CNY | -17.46% |
| 2020 | 821.72 Million CNY | 3085.62% |
| 2019 | 25.79 Million CNY | 2383.35% |
| 2018 | 1.03 Million CNY | -71.5% |
| 2017 | 3.64 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 5.21 Million CNY | -3.99% |
| 2024 Q2 | 10.94 Million CNY | 109.78% |
| 2024 Q3 | 1.99 Million CNY | -81.75% |
| 2023 Q1 | -51.2 Million CNY | 67.17% |
| 2023 FY | -70.95 Million CNY | -111.94% |
| 2023 Q4 | 5.43 Million CNY | 15.49% |
| 2023 Q3 | 4.7 Million CNY | 115.44% |
| 2023 Q2 | -30.47 Million CNY | 40.5% |
| 2022 Q3 | 135.79 Million CNY | -25.63% |
| 2022 Q2 | 182.58 Million CNY | -57.67% |
| 2022 Q1 | 431.35 Million CNY | 236.81% |
| 2022 FY | 594.24 Million CNY | -12.39% |
| 2022 Q4 | -155.99 Million CNY | -214.87% |
| 2021 Q3 | 158.35 Million CNY | 186.14% |
| 2021 Q1 | 336.51 Million CNY | 55.33% |
| 2021 Q2 | 55.34 Million CNY | -83.55% |
| 2021 FY | 678.28 Million CNY | -17.46% |
| 2021 Q4 | 128.07 Million CNY | -19.13% |
| 2020 Q1 | 113.92 Million CNY | 0.0% |
| 2020 FY | 821.72 Million CNY | 3085.62% |
| 2020 Q3 | 152.1 Million CNY | -55.14% |
| 2020 Q2 | 339.05 Million CNY | 197.6% |
| 2020 Q4 | 216.64 Million CNY | 42.43% |
| 2019 FY | 25.79 Million CNY | 2383.35% |
| 2018 FY | 1.03 Million CNY | -71.5% |
| 2017 FY | 3.64 Million CNY | 0.0% |